Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N.

Cell Rep. 2019 May 21;27(8):2411-2425.e9. doi: 10.1016/j.celrep.2019.04.091.

2.

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

Combès E, Andrade AF, Tosi D, Michaud HA, Coquel F, Garambois V, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Moreaux J, Martineau P, Del Rio M, Beijersbergen RL, Vezzio-Vie N, Gongora C.

Cancer Res. 2019 Jun 1;79(11):2933-2946. doi: 10.1158/0008-5472.CAN-18-2807. Epub 2019 Apr 15.

PMID:
30987998
3.

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E.

J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z.

4.

Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities.

Jacqueline C, Bonnefoy N, Charrière GM, Thomas F, Roche B.

Oncoimmunology. 2018 Jun 11;7(8):e1466019. doi: 10.1080/2162402X.2018.1466019. eCollection 2018. Review.

5.

Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance.

Durand M, Dubois F, Dejou C, Durand E, Danger R, Chesneau M, Brosseau C, Guerif P, Soulillou JP, Degauque N, Eliaou JF, Giral M, Bonnefoy N, Brouard S.

Kidney Int. 2018 May;93(5):1154-1164. doi: 10.1016/j.kint.2017.12.004. Epub 2018 Feb 15.

PMID:
29455908
6.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

7.

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Barjon C, Michaud HA, Fages A, Dejou C, Zampieri A, They L, Gennetier A, Sanchez F, Gros L, Eliaou JF, Bonnefoy N, Lafont V.

Oncoimmunology. 2017 Oct 4;7(1):e1379642. doi: 10.1080/2162402X.2017.1379642. eCollection 2017.

8.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

9.

Immune signatures of protective spleen memory CD8 T cells.

Brinza L, Djebali S, Tomkowiak M, Mafille J, Loiseau C, Jouve PE, de Bernard S, Buffat L, Lina B, Ottmann M, Rosa-Calatrava M, Schicklin S, Bonnefoy N, Lauvau G, Grau M, Wencker M, Arpin C, Walzer T, Leverrier Y, Marvel J.

Sci Rep. 2016 Nov 24;6:37651. doi: 10.1038/srep37651.

10.

Loss of Msp1p in Schizosaccharomyces pombe induces a ROS-dependent nuclear mutator phenotype that affects mitochondrial fission genes.

Delerue T, Khosrobakhsh F, Daloyau M, Emorine LJ, Dedieu A, Herbert CJ, Bonnefoy N, Arnauné-Pelloquin L, Belenguer P.

FEBS Lett. 2016 Oct;590(20):3544-3558. doi: 10.1002/1873-3468.12432. Epub 2016 Oct 11.

11.

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F.

Cancer Res. 2016 Sep 15;76(18):5241-52. doi: 10.1158/0008-5472.CAN-15-3164. Epub 2016 Aug 5.

12.

Ribosome recycling defects modify the balance between the synthesis and assembly of specific subunits of the oxidative phosphorylation complexes in yeast mitochondria.

Ostojić J, Panozzo C, Bourand-Plantefol A, Herbert CJ, Dujardin G, Bonnefoy N.

Nucleic Acids Res. 2016 Jul 8;44(12):5785-97. doi: 10.1093/nar/gkw490. Epub 2016 Jun 1.

13.

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF.

Oncoimmunology. 2015 Feb 3;4(5):e1003015. eCollection 2015 May.

14.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.

15.

Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.

Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L.

Oncoimmunology. 2014 Dec 13;3(9):e955684. eCollection 2014 Oct. Review.

16.

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N.

Front Immunol. 2014 Dec 8;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014. Review.

17.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

18.

Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis.

Bastid J, Bonnefoy N, Eliaou JF, Bensussan A.

Oncoimmunology. 2014 Mar 27;3:e28273. eCollection 2014.

19.

Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.

Mathieu AL, Sperandio O, Pottiez V, Balzarin S, Herlédan A, Elkaïm JO, Fogeron ML, Piveteau C, Dassonneville S, Deprez B, Villoutreix BO, Bonnefoy N, Leroux F.

J Biomol Screen. 2014 Aug;19(7):1035-46. doi: 10.1177/1087057114534070. Epub 2014 May 8.

PMID:
24809353
20.

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies.

Merindol N, Riquet A, Szablewski V, Eliaou JF, Puisieux A, Bonnefoy N.

Blood Cancer J. 2014 Apr 25;4:e206. doi: 10.1038/bcj.2014.22. Review. Erratum in: Blood Cancer J. 2014 Oct;4:e254.

Supplemental Content

Loading ...
Support Center